09:07 AM EDT, 08/28/2024 (MT Newswires) -- Azitra ( AZTR ) said Wednesday that it has dosed the first patient in a phase 1b clinical study of its lead drug candidate, ATR-12, for the potential treatment of Netherton syndrome, a rare genetic skin disorder.

The company said the trial will include about 12 adult patients, who will receive twice-daily treatments over 14 days. The study's primary focus is on safety and tolerability, with efficacy and biomarker assessments as secondary and exploratory goals, the company said.

Azitra ( AZTR ) said it plans to release interim safety data early next year and full results in the second half.

Price: 0.6870, Change: -0.02, Percent Change: -2.55